There is no known gene for any major psychiatric disorder, nor is one ever likely to be found, explained Stephan M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego, during an overview of the age of personalized medicine and the role of pharmacogenetics at a session of the 2017 Neuroscience Education Institute Congress.
There is no known gene for any major psychiatric disorder, nor is one ever likely to be found, explained Stephen M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego, during an overview of the age of personalized medicine and the role of pharmacogenetics at a session of the 2017 Neuroscience Education Institute Congress (NEI).
“The classical theory is that genes cause mental illness, but that theory does not work for psychiatry,” he said.
Genes do not code for psychiatric disorders or psychiatric symptoms, but what they do code for is proteins and epigenetic regulators, many of which regulate the efficiency of information processing in brain circuits, which can be visualized with neuroimaging techniques, explained Stahl, who is also chairman of NEI. Currently, psychiatry research is attempting to link circuits upstream to treatment response and downstream to regulatory genes.
The way an individual inherits a psychiatric disorder or responsiveness to one treatment over another is determined by a genotype having a subtle molecular abnormality, which causes abnormal information processing, which leads to behavior with complex functional interactions and emergent phenomena, said Stahl.
Psychiatric disorders, while descriptive and reliable, are not predictive of treatment response or linked to neurology and therefore are not diseases.
“Each psychiatric disorder is likely to represent many diseases, perhaps hundreds,” said Stahl.
The current diagnostic strategy is to attempt to link symptoms domains that cut across psychiatric disorders to inefficient information processing in specific brain circuits.
There are 4 different genotypes that affect drug metabolism:
Stahl finished up the session by discussing how genetic testing fits in modern psychiatric practice.
According to Stahl, pharmacogenomics can add to the modern psychiatric practice because they are:
For treatment-resistant patients, Stahl recommended providers:
“Genetic testing as a clinical tool is still in its infancy,” concluded Stahl. “Genotyping may be especially useful for patients who do not respond to or tolerate a drug as expected. Caution is essential when bringing genetic testing into the selection of treatment in clinical practice.”
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
Just as it is important for retail analysts to understand the choices their customers make and why they may choose not to purchase a specific item, so is it important for the specialty pharmacy industry to understand the actions of prescribers and how the often inefficient prior authorization process affects patient outcomes.
Read More